Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic (B-TEVAR)

July 30, 2026 updated by: Matthew P. Sweet, University of Washington

Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic Aneurysms: An Investigator-Initiated Study

An investigator-initiated, prospective, consecutively enrolling, non-randomized single institution clinical evaluation of the safety and effectiveness of branched and fenestrated-branched endovascular stent grafts to preserve branch vessels when used in the treatment of patients with thoraco-abdominal aortic aneurysms. The study evaluates non-FDA-approved off the shelf and custom made branched and fenestrated-branched stent grafts manufactured by Cook Medical.

The primary objectives of this study are to determine whether fenestrated-branched and branched endovascular grafts are a safe and effective method of treating patients with thoraco-abdominal aortic aneurysms.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

A branched thoracic endograft is a commercially manufactured endograft that has reinforced fenestrations or branches in the graft through which covered stent grafts can be deployed to preserve blood flow into visceral branch vessels.

The branched stent graft is deployed to reline the peri-visceral abdominal aorta. Proximal and distal fixation and seal can be achieved using the branched device, additional Cook Alpha Thoracic devices and/or the Cook Zenith® Flex® device depending on the aortic anatomy.

Once the aortic stent grafts are deployed, the branches are then created. Wires and catheters are used to cross through the reinforced fenestrations into the target visceral arteries. Covered stents are then deployed to extend from the modified aortic graft to the target vessel. The branch stents must create a hemostatic seal with the main endograft as these branches will be constructed within the aneurysm sac. Single or multiple stents may be required for any given branch.

Study Type

Interventional

Enrollment (Estimated)

290

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Sandra Mata-Diaz, MPH
  • Phone Number: 2065988487
  • Email: BTEVAR@uw.edu

Study Locations

  • United States
    • Washington
      • Seattle, Washington, United States, 98104
        • Recruiting
        • University of Washington/Harborview Medical Center
        • Contact:
          • Matthew Sweet, MD
        • Contact:
        • Principal Investigator:
          • Matthew P Sweet, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria

All patients must meet all of the following inclusion criteria to be eligible for enrollment into this study:

  1. Patient is > 18 years of age
  2. Patients who are male or non-pregnant female (females of child bearing potential must have a negative pregnancy test prior to enrollment into the study.
  3. Patient or Legally Authorized Representative has signed an Institutional Review Board (IRB) approved Informed Consent Form
  4. Patient is considered by the treating physician and a second attending physician experienced in the care of patients with aneurysmal disease to be at high risk of open surgical repair due to one or more major medical co-morbidities (i.e. CAD, CHF, COPD, CRI, advanced age, generalized deconditioning, or other.) with ASA of 3 or more.
  5. The patient has reasonable expectation of surviving the B-TEVAR procedure and has a life expectancy of greater than 1 year as determined by the PI and a second attending physician experienced in the care of patients with aneurysmal disease.
  6. The patient has a thoraco-abdominal aortic aneurysm where necessary visceral branch vessels (i.e. the celiac, superior mesenteric, inferior mesenteric, renal and/or dominant spinal arteries) arise from the aneurysm or seal zones necessary for on-label thoracic endovascular repair

  7. Patient has a thoraco-abdominal aortic aneurysm that meets at least one of the following:

    • aneurysm > 5.5 cm in diameter
    • aneurysm has increased in size by 0.5 cm in last 6 months
    • aneurysm is believed to be causing symptoms
  8. Patient has sufficient arterial access (femoral and/or iliac) that will allow delivery of the endovascular device with or without the use of a surgical conduit.
  9. Patient has suitable proximal (aorta) and distal (aorta or iliac) arteries to allow for adequate fixation and seal:

A. Non-aneurysmal proximal aortic seal zone:

  1. Standard BTEVAR cohort will require a length of 25 mm of proximal seal in non-aneurysmal aorta, with or without coverage of the left subclavian artery.
  2. The BTEVAR-CTD cohort will require a length of 30 mm of proximal seal with an outer wall diameter of no less than 15 mm and no greater than 42 mm, and
  3. B. Non-aneurysmal distal aortic or iliac landing zone:
  4. With a length of at least 15 mm,
  5. Aortic seal zone no less than 15 mm and no greater than 42 mm or
  6. Iliac seal zone with an outer wall diameter of no less than 8 mm and no greater than 23 mm.

10. The patient has no more than 5 necessary visceral arteries that require flow preservation.

11. All target visceral artery seal zones are > 4 mm in diameter. 12. Patient must be willing to comply with all required follow-up exams.

5.1.2 Exclusion Criteria

Patients that meet ANY of the following are not eligible for enrollment into the study:

  1. Patient has an active systemic infection
  2. Patient has a mycotic aneurysm.
  3. Patient has a known hypersensitivity to contrast media that is not amenable to pre- treatment.
  4. Patient has an absolute contra-indication to anticoagulation
  5. Patient has known sensitivities or allergies to nitinol (nickel, titanium), polyester, polypropylene, gold,

1. stainless steel, or solder (tin, silver) 6. Patient has a body habitus that would inhibit adequate X-ray visualization of the aorta 7. Patient has a dominant artery to the spinal cord arising from an area of stent graft coverage that is not amenable to preservation using an endovascular branch 8. Patient is currently participating in another investigational device or drug clinical trial 9. Patient is suitable, in the opinion of the investigator, for treatment in accordance with the instructions for use with a legally marketed endovascular prosthesis 10. Patient is suitable, in the opinion of the investigator, for treatment and eligible for enrollment in a manufacturer-sponsored IDE at the investigational site 11. Patient has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations.

12. Patient has a freely ruptured TAAA with hemodynamic instability 13. Patient has unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina) 14. Patient has had a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned within 30 days of the TAAA repair. Adjunctive procedures for treatment of the TAAA (i.e. carotid-subclavian bypass or iliac conduit) are acceptable.

15. Patient has a history of an aortopathic connective tissue disease (e.g. Marfan or Ehlers Danlos syndromes) (This exclusion criteria will not apply for the BTEVAR-CTD substudy cohort) 16. Illicit drug use within the last 12 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: B -TEVAR
Implantation of the B-TEVAR device
Device: B-TEVAR device
Implantation of the Branched Thorcoabdominal aortic anerysm device

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The effectiveness of multi-branched endovascular grafts will be determined by evaluating the proportion of patients that achieve Treatment Success
Time Frame: 12 months post-procedure.
12 months post-procedure.

Secondary Outcome Measures

Outcome Measure
Time Frame
Mortality rates
Time Frame: 12 months
12 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Technical Success
Time Frame: 12 months
Technical Success is defined as successful delivery and deployment of the physician modified graft with preservation of unimpeded flow to those branch vessels intended to be preserved.
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Washington

Investigators

  • Principal Investigator: Matthew P Sweet, MD, University of Washington

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2012

Primary Completion (Estimated)

August 1, 2028

Study Completion (Estimated)

August 1, 2028

Study Registration Dates

First Submitted

June 6, 2013

First Submitted That Met QC Criteria

June 6, 2013

First Posted (Estimated)

June 10, 2013

Study Record Updates

Last Update Posted (Actual)

August 3, 2026

Last Update Submitted That Met QC Criteria

July 30, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • STUDY00004379

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Deidentified data are shared with the Aortic Research Consortium research group

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe